Aprotinin News and Research

RSS
Aprotinin, also known as bovine pancreatic trypsin inhibitor, BPTI (Trasylol, Bayer) is a protein, that is used as medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use is to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death.
Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19

Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19

Researchers identify new therapies that could provide better protection against future COVID-19 variants

Researchers identify new therapies that could provide better protection against future COVID-19 variants

TMPRSS2 protein, a novel target for SARS-CoV-2 drugs

TMPRSS2 protein, a novel target for SARS-CoV-2 drugs

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

Study explains why Omicron infections are less likely to cause severe disease

Study explains why Omicron infections are less likely to cause severe disease

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

Aprotinin inhibits SARS-CoV-2 entry and replication in cells cultures

Aprotinin inhibits SARS-CoV-2 entry and replication in cells cultures

Study: Aprotinin can inhibit virus replication by preventing SARS-CoV2 entry into host cells

Study: Aprotinin can inhibit virus replication by preventing SARS-CoV2 entry into host cells

Researchers identify new drug candidate with potential to treat COVID-19

Researchers identify new drug candidate with potential to treat COVID-19

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Study documents reversal of established medical practices in last decade

Study documents reversal of established medical practices in last decade

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

FDA approves Baxter's TISSEEL for general hemostasis in surgery

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

USPTO grants second patent to Angiochem's EPiC drugs

USPTO grants second patent to Angiochem's EPiC drugs

Pediatric physicians present 12 research abstracts, posters at Cardiology 2011

Pediatric physicians present 12 research abstracts, posters at Cardiology 2011

Omeros receives exclusive license for new series of antifibrinolytic agents

Omeros receives exclusive license for new series of antifibrinolytic agents

Sinobiopharma receives certificate for using Gabexate Mesylate as pharmaceutical raw material

Sinobiopharma receives certificate for using Gabexate Mesylate as pharmaceutical raw material

Qrxpharma forms an alliance with Liaoning Nuokang Medicines to commercialise its venomics assets

Qrxpharma forms an alliance with Liaoning Nuokang Medicines to commercialise its venomics assets